Background and aims: Lipopolysaccharides (LPS) is emerging as a novel risk factor for cardiovascular events (CVEs). Furthermore, in vitro evidence suggested that LPS may elicit proprotein convertase subtilisin/kexin 9 (PCSK9) expression, but their relationship in vivo has not been investigated. Methods: We conducted a post-hoc analysis of a prospective, single centre cohort study of 907 patients with non-valvular atrial fibrillation (AF). At baseline, PCSK9, LPS and NADPH oxidase (sNox2-dp) were measured. PCSK9 and LPS were correlated with the incidence of CVEs. Results: Median PCSK9 and LPS were 1200 [900–1970] and 49.9 [15.0–108.2] pg/ml, respectively. LPS and PCSK9 were significantly correlated (rS 0.378, p < 0.001). Logistic regression analysis showed that LPS was associated with PCSK9 above the median (odds ratio [OR] 1.727 95% confidence interval [CI] 1.147–2.600 p = 0.009). Other factors associated with PCSK9 above the median were sNox2-dp (OR 1.759 C.I. 95% 1.167–2.650, p = 0.007), use of antiplatelet drugs (OR 0.437 95%CI 0.219–0.871 p = 0.017) and high adherence to Mediterranean diet (OR 0.737 95%CI 0.643–0.845 p = 0.001). Olive oil (OR 0.376 95%CI 0.185–0.763, p = 0.001) and wine (OR 0.460 95%CI 0.289–0.733 p = 0.007) were negatively associated with PCSK9. Patients with concomitant high PCSK9 and LPS (LPS ≥88 pg/ml and PCSK9 ≥1570 pg/ml) had an increased risk of CVEs compared to those with low levels (LPS <24.3 pg/ml and PCSK9 <1000 pg/ml, Log-Rank test, p = 0.022). Conclusions: This study demonstrated, for the first time in vivo, that circulating levels of PCSK9 and LPS are associated with a mechanism possibly involving NADPH oxidase activation. Patients with concomitant increase of PCSK9 and LPS showed a higher risk of CVEs.

Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation. a post-hoc analysis from the ATHERO-AF cohort / Pastori, D.; Ettorre, E.; Carnevale, R.; Nocella, C.; Bartimoccia, S.; Del Sordo, E.; Cammisotto, V.; Violi, F.; Pignatelli, P.; Saliola, M.; Casciaro, M. A.; Farcomeni, A.; Rubino, L.; Marchese, C.; Santulli, M.; Vasaturo, F.; Castellani, V.; Menichelli, D.. - In: ATHEROSCLEROSIS. - ISSN 1879-1484. - 2019:(2019). [10.1016/j.atherosclerosis.2019.07.002]

Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation. a post-hoc analysis from the ATHERO-AF cohort

Pastori D.
Co-primo
;
Ettorre E.
Co-primo
;
Carnevale R.;Nocella C.;Bartimoccia S.;Del Sordo E.;Cammisotto V.;Violi F.;Pignatelli P.
Ultimo
;
Saliola M.;Farcomeni A.;Rubino L.;Marchese C.;Santulli M.;Vasaturo F.;Castellani V.;Menichelli D.
2019

Abstract

Background and aims: Lipopolysaccharides (LPS) is emerging as a novel risk factor for cardiovascular events (CVEs). Furthermore, in vitro evidence suggested that LPS may elicit proprotein convertase subtilisin/kexin 9 (PCSK9) expression, but their relationship in vivo has not been investigated. Methods: We conducted a post-hoc analysis of a prospective, single centre cohort study of 907 patients with non-valvular atrial fibrillation (AF). At baseline, PCSK9, LPS and NADPH oxidase (sNox2-dp) were measured. PCSK9 and LPS were correlated with the incidence of CVEs. Results: Median PCSK9 and LPS were 1200 [900–1970] and 49.9 [15.0–108.2] pg/ml, respectively. LPS and PCSK9 were significantly correlated (rS 0.378, p < 0.001). Logistic regression analysis showed that LPS was associated with PCSK9 above the median (odds ratio [OR] 1.727 95% confidence interval [CI] 1.147–2.600 p = 0.009). Other factors associated with PCSK9 above the median were sNox2-dp (OR 1.759 C.I. 95% 1.167–2.650, p = 0.007), use of antiplatelet drugs (OR 0.437 95%CI 0.219–0.871 p = 0.017) and high adherence to Mediterranean diet (OR 0.737 95%CI 0.643–0.845 p = 0.001). Olive oil (OR 0.376 95%CI 0.185–0.763, p = 0.001) and wine (OR 0.460 95%CI 0.289–0.733 p = 0.007) were negatively associated with PCSK9. Patients with concomitant high PCSK9 and LPS (LPS ≥88 pg/ml and PCSK9 ≥1570 pg/ml) had an increased risk of CVEs compared to those with low levels (LPS <24.3 pg/ml and PCSK9 <1000 pg/ml, Log-Rank test, p = 0.022). Conclusions: This study demonstrated, for the first time in vivo, that circulating levels of PCSK9 and LPS are associated with a mechanism possibly involving NADPH oxidase activation. Patients with concomitant increase of PCSK9 and LPS showed a higher risk of CVEs.
File allegati a questo prodotto
File Dimensione Formato  
Pastori_Interaction_2019.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 640.71 kB
Formato Adobe PDF
640.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1310453
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact